O-[(2-methoxyphenyl)methyl]hydroxylamine | 161146-52-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: O-[(2-methoxyphenyl)methyl]hydroxylamine
• 英文别名: O-(2-tetrahydronaphthalen-2-yl)ethanone；O-(2-methoxybenzyl)hydroxylamine；O-(o-methoxy)benzylhydroxylamine
• CAS: 161146-52-7
• 化学式: C₈H₁₁NO₂
• mdl: MFCD11594377
• 分子量: 153.181
• InChiKey: OOJGDPODQAPHLV-UHFFFAOYSA-N

物化性质

• 沸点：
  271.6±23.0 °C(Predicted)
• 密度：
  1.095±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  44.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  O-[(2-methoxyphenyl)methyl]hydroxylamine 在 碳酸氢钠 、 一水合肼 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成 N-(2-Amino-ethyl)-O-(2-methoxy-benzyl)-hydroxylamine
  参考文献：
  名称：

  1-Benzyloxy-4,5-dihydro-1H-imidazol-2-yl-amines, a novel class of NR1/2B subtype selective NMDA receptor antagonists

  摘要：

  Screening of the Roche compound depository led to the identification of (1-benzyloxy-4,5-dihydro-1H-imidazol-2-yl)-butyl amine 4, a structurally novel NR1/2B Subtype selective NMDA receptor antagonist. The structure-activity relationships developed in this series resulted in the discovery of a novel class of potent and selective NMDA receptor blockers displaying activity in vivo. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00713-3
• 作为产物：
  描述：

  2-甲氧基苯甲醇 在 一水合肼 、 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 4.5h， 生成 O-[(2-methoxyphenyl)methyl]hydroxylamine
  参考文献：
  名称：

  Synthesis, in Vitro Antimycobacterial and Antibacterial Evaluation of IMB-070593 Derivatives Containing a Substituted Benzyloxime Moiety

  摘要：

  合成并评价了一系列含有取代苯甲酰肟基团且脂溶性显著提高的新型IMB-070593衍生物的体外抗分枝杆菌和抗菌活性。我们的结果显示，目标化合物19a–m对革兰氏阳性菌具有相当高的活性（MIC：<0.008–32 µg/mL），尽管它们对革兰氏阴性菌的活性通常低于参考药物。特别是化合物19h、19j、19k和19m对所有测试的革兰氏阳性菌株显示出良好的活性（MICs：<0.008–4 µg/mL），包括对环丙沙星（CPFX）和/或左氧氟沙星（LVFX）耐药的甲氧西林敏感金黄色葡萄球菌（MSSA）、甲氧西林耐药金黄色葡萄球菌（MRSA）和表皮葡萄球菌（MSSE）。此外，化合物19l（MIC：0.125 µg/mL）对抗ATCC 27294的结核杆菌H37Rv的活性是母体化合物IMB070593、环丙沙星和左氧氟沙星的2–4倍。

  DOI：

  10.3390/molecules18043872

文献信息

• [EN] SUBSTITUTED BICYCLIC COMPOUNDS<br/>[FR] COMPOSÉS BICYCLIQUES SUBSTITUÉS
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2016028959A1

  公开（公告）日：2016-02-25

  Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V) and/or a salt thereof, wherein R1 is OH or OP(O)(OH)2, and X1, X2, X3, R2, R2a, Ra, Rb, and Rc are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

  揭示了Formula（I）、（II）、（III）、（IV）和（V）及/或其盐的化合物，其中R1为OH或OP（O）（OH）2，X1、X2、X3、R2、R2a、Ra、Rb和Rc在此处有定义。还揭示了将这些化合物用作选择性G蛋白偶联受体S1P1的激动剂的方法，以及包含这些化合物的药物组合物。这些化合物在治疗、预防或减缓多种治疗领域的疾病或疾病的进展方面是有用的，如自身免疫疾病和血管疾病。
• NOVEL VASCULAR LEAKAGEAGE INHIBITOR
  申请人：Industry-Academic Cooperation Foundation, Yonsei University

  公开号：US20140378399A1

  公开（公告）日：2014-12-25

  The present disclosure relates to a novel vascular leakage inhibitor. The novel vascular leakage inhibitor of the present invention inhibits the apoptosis of vascular endothelial cells, inhibits the formation of actin stress fibers induced by VEGF, and enhances the cortical actin ring structure, thereby inhibiting vascular leakage. Accordingly, the vascular leakage inhibitor of the present invention can prevent or treat various diseases caused by vascular leakage. Since the vascular leakage inhibitor of the present invention is synthesized from commercially available or easily synthesizable pregnenolones, it has remarkably superior feasibility of commercial synthesis.

  本公开涉及一种新型血管渗漏抑制剂。本发明的新型血管渗漏抑制剂抑制血管内皮细胞凋亡，抑制由VEGF诱导的肌动蛋白应激纤维的形成，并增强皮质肌动蛋白环结构，从而抑制血管渗漏。因此，本发明的血管渗漏抑制剂可以预防或治疗由血管渗漏引起的各种疾病。由于本发明的血管渗漏抑制剂是由商业可获得或易于合成的孕酮合成的，因此具有明显优越的商业合成可行性。
• Copper-Catalyzed Synthesis of Trisubstituted Isoxazoles via a Cascade Cyclization–Migration Process
  作者：Masafumi Ueda、Shoichi Sugita、Aoi Sato、Tetsuya Miyoshi、Okiko Miyata

  DOI：10.1021/jo301358h

  日期：2012.10.19

  An atom-economical, catalytic, and regioselective synthesis of 3,4,5-trisubstituted isoxazoles has been successfully developed. Treatment of O-arylmethyl alkynyl oxime ethers with 5 mol % of Cu(OTf)2 in chlorobenzene at reflux gave 4-arylmethylisoxazoles in good to excellent yields via the sequential intramolecular addition of the oxime moiety to the alkyne with subsequent 1,3-migration of the arylmethyl

  已经成功地开发了3,4,5-三取代的异恶唑的原子经济，催化和区域选择性合成。在回流下用5 mol％的Cu（OTf）2在氯苯中的O-芳基甲基炔基肟醚处理，通过依次将肟部分分子内添加到炔烃中并随后进行1,3迁移，以良好的收率获得了优良的4-芳基甲基异恶唑。芳基甲基的基团。
• Design, Synthesis, Molecular Docking and Biological Evaluation of Novel Coumarin-Oxime Ether Derivatives as COX-2 Inhibitors
  作者：M. Vijaya Bhargavi、P. Shashikala、M. Sumakanth、Shravan Kumar Gunda

  DOI：10.14233/ajchem.2017.20865

  日期：——

  Coumarin-oxime ether derivatives (14-25) were synthesized by an efficient and straight forward procedure from the reaction of 3-acetyl coumarin (1) and o-substituted benzyl hydroxyl amines (2-13) in pyridinium p-toluenesulfonate/dichloromethane (PPTS/DCM) at reflux temperature. High yields and simple operations are important features of this methodology. The method is very useful for the construction of many biologically active oxime ether derivatives. The structures of the synthesized compounds are established based on IR, NMR and MASS spectrometry. Molecular docking studies were performed against selective COX-2 enzyme using Discovery Studio v3.5. The compounds with good LibDock score were screened for their in vivo anti-inflammatory activity by paw edema method, employing indomethacin as a reference standard.

  香豆素-肟醚衍生物（14-25）是由 3-乙酰基香豆素（1）和邻取代苄基羟胺（2-13）在吡啶对甲苯磺酸盐/二氯甲烷（PPTS/DCM）中于回流温度下反应合成的，该过程高效且简单。产量高、操作简单是该方法的重要特点。该方法非常适用于制造许多具有生物活性的肟醚衍生物。根据红外光谱、核磁共振和质谱分析，确定了合成化合物的结构。使用 Discovery Studio v3.5 针对选择性 COX-2 酶进行了分子对接研究。以吲哚美辛为参考标准，采用爪水肿法对 LibDock 得分较高的化合物进行了体内抗炎活性筛选。
• Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof
  申请人：Fensholdt Jef

  公开号：US20070244117A1

  公开（公告）日：2007-10-18

  The invention relates to compounds of general formula I wherein D, E, F, G, W, Y, R 1 , A, R 9 , X, B, R 8 are as defined herein, and pharmaceutically acceptable salts, hydrates, or solvates thereof, for use—alone or in combination with one or more other pharmaceutically active compounds—in therapy, for treating diseases associated with deregulated angiogenesis, such as cancer.

  本发明涉及一般式I的化合物，其中D、E、F、G、W、Y、R1、A、R9、X、B、R8如本文所定义，并且其药学上可接受的盐、水合物或溶剂化物，用于治疗与异常血管生成相关的疾病，如癌症，可单独使用或与一个或多个其他药理活性化合物联合使用。